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Abstract
Aim: The aim of this study was to investigate heart rate variability (HRV) in a clinical sample of
female adolescents with anxiety disorders (AD) and⁄or major depressive disorder (MDD) compared
with healthy controls and to assess the effect of selective serotonin reuptake inhibitors (SSRI) on HRV.
Methods: Heart rate variability was measured in adolescent female psychiatric patients with AD
and⁄or MDD (n = 69), mean age 16.8 years (range: 14.5–18.4), from 13 out-patient clinics and in
healthy controls (n = 65), mean age 16.5 years (range: 15.9–17.7). HRV was registered in the sitting
position during 4 min with no interventions.
Results: Logarithmically transformed high frequency HRV (HF), low frequency HRV (LF) and
standard deviation of inter beat intervals (SDNN) were lower in the clinical sample compared with the
controls (Cohen’s d for HF = 0.57, LF = 0.55, SDNN = 0.60). This was not explained by body mass
index, blood pressure or physical activity. Medication with SSRI explained 15.5% of the total variance
of HF, 3.0% of LF and 6.5% of SDNN.
Conclusions: Adolescent female psychiatric patients with AD and⁄or MDD show reduced HRV compared with
healthy controls. Medication with SSRI explained a part of this difference.
Re-use of this article is permitted in accordance with
the Creative Commons Deed, Attribution 2.5, which
does not permit commercial exploitation.
INTRODUCTION
The prevalence of self-reported symptoms of anxiety in ado-
lescents has increased more than threefold during the last
two decades in Sweden, reaching 33.1% in females and
11.9% in males (1). International studies show great dis-
crepancies in the prevalence of anxiety disorders (AD), with
1-year prevalence ranging 2.8–18.4% in 15–18 year olds.
The lifetime prevalence of major depressive disorder
(MDD) of around 20% at the end of adolescence (2).
Adolescents show high correlations between self-report
measures of anxiety and depression and high comorbidity
rates of AD and MDD. AD tend to precede the onset of
depressive disorders and late adolescents show higher com-
orbidity rates than younger children.
The high comorbidity rates may be partly explained by
overlapping items and poor discriminant validity between
depression and anxiety assessment scales that could lead to
anoverestimationoftheassociationofthetwoconstructs(3).
Clarke and Watson (4) proposed that anxiety and depres-
sion share a common component of negative affect (NA)
and that NA accounts for symptom overlap and comorbidi-
ty. NA is a general factor of subjective distress and encom-
passes mood states such as fear, sadness, anger, guilt, scorn
and disgust. They further suggested that anxiety and depres-
sion can be differentiated by increased physiological
hyperarousal (autonomic hyperactivity and motor tension)
speciﬁcally in anxiety and low positive affect (PA) speciﬁ-
cally for depression. PA includes feelings of joy, energy,
enthusiasm, interest, alertness and self-conﬁdence and low
PA indicates anhedonia (4). Longitudinal data conﬁrm that
anxiety- and depressive disorders are caused by a combina-
tion of shared and disorder-speciﬁc factors in adults (5).
Adult measures of tripartite constructs have been modiﬁed
for children and adolescents, and the concurrent and discri-
minant validity of anxiety and depression in youth has been
investigated and new assessment scales developed (6).
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whether hyperarousal is speciﬁc for anxiety. HRV provides
a window onto autonomic regulation of the heart. High fre-
quency of HRV (HF) is related to vagal activity and includes
the respiratory sinus arrhythmia (RSA) when the breathing
rate is normal. Low HF has been interpreted as a sign of
hyperarousal. Recent studies suggest that also low
frequency HRV (LF) mainly reﬂects vagal inﬂuence (7).
Evidence for an association between decreased vagal tone
and AD (8,9), and by evidence for unchanged vagal tone in
patients with MDD (10) support Watson’s model. However,
decreased vagal tone in HRV measures have also been dem-
onstrated in patients with depression (11) contradicting the
model.
It has been debated whether the ﬁndings of the decreased
HRV in patients with MDD is explained by comorbidity of
AD (12) and⁄or decreased physical activity (13). Recent
studies of large samples show that medication with Selec-
tive Serotonin Reuptake Inhibitors (SSRI) contributes to
the decrease of HRV in patients with both MDD (14) and
AD (15).
A large population based study of children aged 10–
13 years, showed more complex and gender dependent rela-
tionships between HRV and measures of anxiety and
depression than previously presented (16). A female pre-
dominance of mood disorders occurs in the developmental
transition in mid puberty. Changes in androgen and oestro-
gen levels have been proposed as the causal factors (17) and
may also inﬂuence HRV.
One of the most prominent confounding factors, when
studying the relationship between HRV and AD and⁄or
MDD is probably physical activity. Physical activity is asso-
ciated with increase of HRV in adults (18) and predicts
HRV in healthy adolescents (19). Other possible confound-
ing factors in this context are cardiovascular risk factors, as
HRV is altered among patients with ischaemic heart disease
when compared with their age-matched controls (20).
Already in adolescence, increased body mass index (BMI)
(21), hypertension (22) and hyperglycaemia (23) are associ-
ated with decreased HRV. Thus, in a study designed to
investigate the relationship between HRV and AD⁄MDD
these parameters must be controlled for.
This study aimed to investigate HRV in female adolescent
psychiatric patients with AD, MDD and comorbidity of
AD⁄MDD compared with age matched controls, after
adjustment for cardiovascular risk factors such as BMI, sys-
tolic (SBP) and diastolic blood pressure (DBP), p-glucose
and physical activity. The impact of SSRI on HRV was also
assessed.
METHODS
The clinical sample consisted of adolescent girls (n = 69)
with a mean age 16.8 years (range: 14.5–18.4 years) who
were psychiatric patients and had a Development and Well-
being Assessment (DAWBA) validated diagnosis of one or
several AD (general anxiety disorder, social phobia, speciﬁc
phobia, panic disorder, separation anxiety, post-traumatic
stress disorder) and⁄or MDD. The subjects had ongoing
treatment contact (median duration 11 months) at one of
13 open psychiatric clinics for children and adolescents sit-
uated in the centre of Stockholm, surrounding suburbs or in
smaller towns nearby. The staff at the clinics (psychiatrists,
psychologists and social workers) asked their patients about
participation and gave them written information. From
what has been reported from the staff, 85% of the informed
patients participated. The reason not to participate was fear
of blood sampling.
Psychiatric assessment by child and adolescent psychia-
trists or psychologist and DAWBA-interview were used to
establish case status of AD and⁄or MDD as the major diag-
nosis⁄es. Patients with severe autism or psychotic symptoms
were not recruited to the study. The DAWBA interviewers
worked from computerized versions of the test in which all
information had been collated by software. Two of the
authors independently rated the computer-generated infor-
mation to decide whether or not to accept the computer
diagnoses. Six subjects were denied participation because
the DAWBA was incomplete or could not conﬁrm diagnose
of AD and⁄or MDD (Fig. 1). The measurements were per-
formed at the patient’s clinic by the ﬁrst author and an assis-
tant and followed the same order in all subjects.
The controls consisted of adolescent girls (n = 66), with a
mean age of 16.5 years (range: 15.9–17.7 years). Oral and
written information about the study was given to the stu-
dents in their classrooms. About 80% of the informed stu-
dents participated, the participation ratio being similar
across all schools. The main reasons not to participate were
fear of blood sampling and reluctance to miss school-hours.
The clinical sample and the controls were age matched
and recruited from similar areas. Exclusion criteria for both
samples were diabetes, thyroid dysfunction, pregnancy and
more than 5% missing or distorted data in any registered
HRV segment. The study was approved by the Regional
and Central Ethic’s Committee at Karolinska Institutet.
Heart rate variability – measurement and processing
The subjects were sitting upright in silence with spontane-
ous breathing. No body movements were allowed during
the procedure. None of the subjects had clinical signs or
symptoms of infectious disease. Use of tobacco (snuff and
smoking of cigarettes) or intake of tea, coffee, caffeine con-
taining soft drinks or beta stimulant asthma medication was
not allowed 1 h prior to the measurements. The HRV regis-
tration was preceded by 15 min of rest. HRV was measured
during 2 min · 2, with blood pressure checked in between.
This was a modiﬁed version of a 12 min protocol (24). The
mean of the two periods for HF; LF and SDNN was calcu-
lated and then logarithmically transformed. The 2 min · 2
HRV registration has previously been shown to generate
stable results in repeated measures 6 month later in the
non-clinical sample, supporting that short registrations
without standardized interventions can capture HRV differ-
ences of possible predictive and clinical value (19).
The square root of variance, i.e. the standard deviation of
the interbeat intervals (SDNN), was used as a time domain
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variability in the period of recording. In spectral analyses
the variability distributes as a function of frequency. The HF
(0.15–0.4 Hz) and LF (0.04–0.15 Hz) were used as fre-
quency domain measures. The equipment was a I-330-C-2
Physiological Monitoring System (J&J Engineering; Poul-
sbo, WA, USA), and c-Stress customized software (PBM
Systems, Stockholm, Sweden). The electrocardiogram
(ECG) was recorded from electrodes placed on the left and
right wrist with a sampling rate of 1024 Hz. Interbeat inter-
vals were calculated on-line using an R-wave peak detection
algorithm and stored on a PC for off-line processing. Fourier
analysis was performed on 2-min segments of detrended
Figure 1 Least square means of HF (a), LF (b) and SDNN (c) in the controls
and the diagnostic subgroups of anxiety disorders (AD), major depressive dis-
order (MDD) and comorbidity of AD⁄MDD with or without selective serotonin
reuptake inhibitors medication. Adjustment was carried out for BMI, systolic
and diastolic blood pressure, p-glucose and physical activity.
Figure 2 (a) Exclusion procedure of the clinical sample. (b) Exclusion proce-
dure of the non-clinical sample.
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values were logarithmically transformed. Inter-beat-inter-
vals were scanned manually for ectopic beats and artefacts,
which were replaced with cubic spline interpolation.
Psychiatric self-assessment scales and interviews
Development and Wellbeing Assessment (DAWBA) is a
semi-structured diagnostic interview designed to generate
ICD-10 and DSM-IV psychiatric diagnoses on 5–17 year
olds. DAWBA has consistently generated sensible estimates
of prevalence and association with risk factors. When com-
pared with clinical diagnoses, DAWBA diagnoses support
good validity (25). In this study, the information was only
collected from the patients and not from parents and teach-
ers.
Beck’s Depression Inventory (BDI) is a frequently used
rating scale in adolescent psychiatry for screening and
measuring symptoms of depression over a 2 week period
prior to the assessment. A modiﬁed version, BDI-II, has
been developed and shown good psychometric properties
in non-clinical adolescent samples (26). When this study
was designed, the BDI-II was, however, not yet validated
for the Swedish version and BDI-A1 is used instead. BDI
consists of 21 items rated on a 4-point scale and yields a
total score by summation of the ratings for the individual
items.
Beck’s Anxiety Inventory (BAI) is often used in adoles-
cent research and clinical practice, with good psychometric
properties reported (27). BAI contains 21 items assessing
the degree to which the respondent has been affected by the
physical or cognitive symptoms of anxiety during the past
week. BAI items are also meant to reﬂect panic attack
symptoms.
Strengths and Difﬁculties Questionnaire (SDQ) is an
internationally used screening instrument for mental health
problems in children and teenagers (28). It is made up of 25
statements regarding psychological attributes and behav-
iours, forming ﬁve subscales: hyperactivity⁄inattention,
emotional symptoms, conduct problems, peer problems and
pro-social behaviours. All subscales except the pro-social
scale are summarized to generate a total difﬁculties score.
In this study, only the emotional scale (SDQ-em) was used.
Acceptable psychometric properties for the self-report ver-
sion of SDQ for adolescent have been shown in the previ-
ous studies and SDQ-em has been shown to have valid
ability to differentiate cases of AD and MDD in this age
group (29).
Physical activity was reported on a ﬁve point scale as
frequency of exercising with hard breathing and sweat-
ing (never, seldom, once a week, twice a week, >twice a
week).
Blood chemistry and body mass index
Capillary blood samples were drawn right after the ECG
registration and non-fasting p-glucose was analysed with a
portable Heamocue Glucose System devise (30). Weight
and length were measured and BMI calculated [BMI =
weight (kg)⁄length (m
2)].
Statistical analyses
Variables with a positively skewed distribution were loga-
rithmically transformed. Heart rate and logarithmically
transformed HRV parameters were normally distributed in
the clinical and controls sample. Groups were compared in
a two tailed fashion, with the two sample t-test or, when
normal distributions were absent, with Mann–Whitney’s
U-test. Relations between psychiatric self-assessment and
HRV indices were assessed by Pearson’s product-moment
correlation, and when variables were of an ordinal nature,
Spearman’s rank correlation was used. Partial correlations
were used to remove the effect of heart rate (HR), BMI, sys-
tolic (SBP) and diastolic blood pressure (SBP), p-glucose
and physical activity on HRV. Partial correlations are
Table 1 Comparison of back ground characteristics in the clinical sample and
in the controls
Clinical sample
n=6 0
1
Controls
n=5 3
X2⁄z-value⁄
t-value
N⁄mean
(SD)
N⁄mean
(SD)
Parents’ occupational status
(n = 58)
2
Both parents employed 44 39 0.96 ns
At least one parent
unemployed
10 14
Family situation
(n = 56)
2
Living with two parents 39 38 0.06 ns
Living with single parent 17 15
Parents’ ethnical background
(n = 58)
2
At least one parent
Swedish
55 44 4.01*
Both parents of foreign
origin
39
Daily smoking of cigarettes
(n = 58)
2
No 49 46
Yes 9 7 0.12 ns
Physical Activity Index
(n = 58)
3.11 3.47 Z = 1.56 ns
Body Mass Index
(n = 57)
20.8 (2.2) 22.3(3.7) t = 2.63*
p-glucose
(n = 59)
6.7 (2.2) 5.5 (0.7) Z = )3.41**
Systolic blood pressure
(n = 58)
109.7 (11.6) 111.4 (9.3) t = 0.85 ns
Diastolic blood pressure
(n = 57)
68.5 (9.7) 67.2 (7.5) t = )0.76 ns
BDI (n = 53) 25.4 (12.0) 9.2 (8.6) t = )8.1***
BAI (n = 53) 22.3 (10.9) 12.0 (9.0) t = )5.5***
SDQ-em (n = 53) 7.2 (1.6) 3.5 (2.3) Z = )7.3***
1The clinical sample consisted of 60 subjects but each subject has not deliv-
ered full data sets.
2Parents occupational, family situation, ethnicity, snuff and cigarette consump-
tion are used only to describe the representativity of the samples and are not
introduced as covariates in the calculations.
***t- and z-values were signiﬁcant at p < 0.001, **p < 0.01,*p < 0.05, ns =
non-signiﬁcant.
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where HR, BMI, SBP, DBP, p-glucose and physical activity
have acted as predicting variables on the respective HRV
indices. Such operations render the underlying correlations
when the effects of the predicting variables have been
removed. Linear multiple regressions with BMI, SBP, DBP,
p-glucose and physical activity as co-variates were applied
to all HRV-variables. The results from these two strategies
did not, contradict each other, but served to further support
the underlying theories.
Cohen’s d were calculated as effect sizes using the pooled
standard deviations (d =m 1 –m 2⁄ [(r1
2 + r2
2)⁄2]) (Cohen,
1988). A d of 0.20 represents a small effect size, 0.50 repre-
sents a medium effect size and 0.80 represents a large effect
size. The three diagnostic subgroups of the clinical sample
were analysed with one-way ANOVA and compared by
contrast analysis. The ANOVA was executed by the method
of variance components with diagnosis and SSRI used as
random factors. This method has the advantage of revealing
the relative inﬂuence of diagnosis and SSRI on the residual
variation, when the effects of the ﬁxed factors have been
removed. The variables HR, BMI, SBP, DBP, p-glucose and
physical activity served as ﬁxed factors.
RESULTS
Sample characteristics
From the original clinical sample (n = 73), one subject was
excluded because of pregnancy and three because of
somatic disorders (diabetes and hypothyreosis). Another
seven patients were excluded as a result of >5% missing or
distorted HRV data and two subjects dropped out. The ﬁnal
clinical sample included 60 subjects, (AD n = 20, MDD
n = 11, comorbidity of AD and MDD n = 29). The clinical
sample contained 23 patients with anti depressant medica-
tion of which 22 had SRRI medication (citalopram, ﬂuoxe-
tin and sertralin) and one had a tricyclic antidepressant
(tryptizol). No patients were taking Seretonin Noradrenalin
Reuptake Inhibitors. From the original control sample
(n = 66) one subject was excluded as a result of thyrotoxico-
sis and twelve were excluded because of >5% missing or dis-
torted HRV data, rendering a ﬁnal control sample of 53
subjects (Fig. 2a,b).
Background factors such as parent unemployment or sin-
gle parent household did not differ between the clinical
sample and the controls. The control sample contained a
higher ratio of subjects with parents of non-Swedish origin.
Use of tobacco, SBP, DBP and self-reported physical activ-
ity showed no signiﬁcant differences between the clinical
sample and the controls, but BMI was lower and p-glucose
higher in the clinical sample (Table 1). The difference of
p-glucose between the samples was partly explained by four
subjects in the clinical sample with high p-glucose
(>12 mmol⁄L) but no decrease of HRV compared with the
rest of the subjects in this sample (data not shown).
Linear regression models applied on HF, LF and SDNN
in both samples showed signiﬁcant contributions from
physical activity and DBP only in the non-clinical sample.
BMI, p-glucose and SBP showed no contributions in any of
the samples (Table 2).
Comparison of HRV in the clinical sample vs. controls
The HF, LF and SDNN were signiﬁcantly lower (med-
ium effect sizes) in the clinical sample with diagnoses
of AD and⁄or MDD compared with the controls. No
difference of heart rate was found between the groups
(Table 3).
Analyses comparing diagnostic subgroups of the clinical
sample
No signiﬁcant differences of HF, LF or SDNN were found
between the diagnostic subgroups (AD, MDD and comor-
bidity of AD⁄MDD). Patients with AD had lower LF
(t = 2.02*), MDD had lower LF (t = 2.22*) and SDNN
(t = 2.60*) and comorbidity of AD⁄MDD had lower SDNN
(t = 2.12*) vs. the controls, when controlled for BMI, p-glu-
cose, systolic and diastolic blood pressure and physical
activity (Table 4).
Table 2 Linear Regression Models showing the effect of BMI, p-glucose, SBP, DBP and physical activity on each HRV parameter (a) in the non-clinical sample (b) in
the clinical sample
HF LF SDNN
Beta (CI) Beta (CI) Beta (CI)
(a) Non-clinical sample
BMI 0.12 ()0.16 to 0.40) ns )0.19 ()0.47 to 0.09) ns )0.05 ()0.33 to 0.23) ns
p-glucose )0.01 ()0.27 to 0.25) ns 0.00 ()0.27 to 0.26) ns )0.06 ()0.32 to 0.21) ns
SBP 0.06 ()0.26 to 0.38) ns 0.23 ()0.09 to 0.55) ns 0.13 ()0.19 to 0.45) ns
DBP )0.37 ()0.68 to )0.07) )0.35 ()0.66 to )0.04) )0.41 ()0.71 to 0.10)
Physical activity 0.35 (0.09 to 0.61) 0.30 (0.04 to 0.56) 0.31 (0.05 to 0.56)
(b) Clinical sample
BMI )0.03 ()0.32 to 0.27) ns )0.25 ()0.53 to 0.03) ns )0.22 ()0.50 to 0.07) ns
p-glucose )0.05 ()0.36 to 0.26) ns 0.04 ()0.25 to 0.34) ns 0.07 ()0.24 to 0.37) ns
SBP )0.12 ()0.49 to 0.26) ns )0.11 ()0.48 to 0.25) ns )0.10 ()0.47 to 0.27) ns
DBP 0.02 ()0.37 to 0.41) ns 0.14 ()0.23 to 0.51) ns 0.05 ()0.33 to 0.43) ns
Physical activity )0.07 ()0.36 to 0.23) ns )0.12 ()0.40 to 0.16) ns )0.08 ()0.36 to 0.21) ns
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Signiﬁcant differences of HF, LF and SDNN in the clinical
sample vs. controls as well as between the diagnostic sub-
groups (AD, MDD, AD + MDD) vs. controls were only
seen in patients with SSRI medication. Medication with
SSRI explained 15.5% of the total variance of HF, 3.0% of
LF and 6.5% of SDNN between the clinical sample and the
controls when adjusted for BMI, SBP, DBP, p-glucose,
physical activity. The results remained similar when self-
assessed symptom severity (BDI, BAI and SDQ-em) were
introduced as covariates (graph 1, Table 4).
The subgroups of patients with SSRI medication (n = 23)
vs. patients without SSRI medication (n = 37) did not have
signiﬁcantly different BDI or BAI scores, but SDQ-em
showed higher scores in the group without medication
(Mann–Whitney U-test: z-value = )2.0, p-value 0.04). No
differences of the covariates (BMI, systolic and diastolic
blood pressure, p-glucose, physical activity) were identiﬁed
between the subgroups (data not shown).
Correlations of HRV and symptoms of anxiety and⁄or
depression
In the control sample, signiﬁcant correlations between HF
and depressive symptoms (BDI) were found (correlation
coefﬁcient = )0.28 p = 0.047) after adjustment for BMI,
SBP; DBP and p-glucose. This correlation did not remain
signiﬁcant when physical activity was introduced as a co-
variate. In the control sample, physical activity correlated to
HF (0.38**), LF (0.33*), SDNN (0.34*) (Table 5). No signif-
icant correlations were found between the HRV indices and
symptoms of anxiety (BAI) in the controls.
DISCUSSION
The main ﬁnding of this study is that HRV (HF, LF and
SDNN) was signiﬁcantly reduced in a group of adolescent
psychiatric female patients with AD and⁄or MDD com-
pared with healthy controls. The differences were of
Table 3 Differences of mean heart rate and logarithmically transformed HF, LF,
SDNN of the clinical sample compared with the controls
Clinical
sample
Clinical
sample
M( S D )
n=6 0
Controls
M( S D )
n=5 3
Mean
difference
X1)X2 Cohens d t-value
Log HF Total 5.46 (0.86) 5.94 (0.83) )0.46 0.57 2.96**
SSRI) 5.64 (0.88) )0.30 0.35 1.61 ns
SSRI+ 5.22 (0.79) )0.72 0.89 3.45**
Log LF Total 5.48 (0.86) 5.94 (0.87) )0.48 0.53 2.86**
SSRI) 5.58 (0.93) )0.36 0.40 1.86 ns
SSRI+ 5.36 (0.76) )0.58 0.71 2.73**
Log SDNN Total 3.88 (0.34) 4.08 (0.33) )0.20 0.60 3.19**
SSRI) 3.94 (0.36) )0.14 0.41 1.93 ns
SSRI+ 3.81 (0.30) )0.27 0.86 3.38**
Heart rate Total 73.2 (9.63) 76.2 (9.48) )2.8 0.31 1.66 ns
SSRI) 72.9 (10.32) )3.3 0.33 1.52 ns
SSRI+ 72.9 (8.46) )3.3 0.37 1.41 ns
ns = non-signiﬁcant.
Patients with SSRI medication (SSRI+) and without SSRI medication (SSRI))
are analysed separately.
**Signiﬁcant at p < 0.01.
Table 4 The SSRI effect on the contrast estimates of HF, LF and SDNN in all patients and the diagnostic subgroups vs. the controls, when controlled for BMI, p-glu-
cose, systolic and diastolic blood pressure and physical activity
HF LF SDNN
Contrast estimate (CI) t-value Contrast estimate (CI) t-value Contrast estimate (CI) t-value
Patients vs. controls 0.41 (0.05 to 0.77) 2.26* 0.51 (0.14 to 0.89) 2.73** 0.21 (0.07 to 0.36) 2.98**
Without SSRI 0.20 ()0.22 to 0.61) 0.94 ns 0.37 ()0.08 to 0.82) 1.63 ns 0.13 ()0.03 to 0.31) 1.62 ns
With SSRI 0.63 (0.20 to 1.07) 2.94** 0.62 (0.17 to 1.06) 2.77** 0.27 (0.11 to 0.44) 3.25**
AD vs. controls 0.44 ()0.04 to 0.92) 1.81 ns 0.51 (0.01 to 1.01) 2.02* 0.18 ()0.01 to 0.37) 1.87 ns
Without SSRI 0.25 ()0.29 to 0.79) 0.93 ns 0.35 (0.22 to 0.93) 1.22 ns 0.15 ()0.07 to 0.37) 1.37 ns
With SSRI 0.88 (0.08 to 1.69) 1.18* 0.88 (0.04 to 1.74) 2.07* 0.24 ()0.08 to 0.56) 1.48 ns
MDD vs. controls 0.36 ()0.24 to 0.96) 1.19 ns 0.70 (0.07 to 1.32) 2.22* 0.31 (0.07 to 0.55) 2.60*
Without SSRI 0.00 (0.74 to 0.75) 0.99 ns 0.60 ()0.19 to 1.38) 1.51 ns 0.21 ()0.09 to 0.50) 1.37 ns
With SSRI 0.86 ()0.02 to 1.75) 1.93 ns 0.84 ()0.09 to 1.77) 1.78 ns 0.46 (0.10 to 0.81) 2.57*
AD + MDD vs. controls 0.41 ()0.05 to 0.87) 1.78 ns 0.42 ()0.05 to 0.89) 1.77 ns 0.19 (0.01 to 0.37) 2.12*
Without SSRI 0.23 ()0.29 to 0.87) 0.32 ns 0.36 ()0.25 to 0.97) 1.18 ns 0.14 (0.09 to 0.37) 1.23 ns
With SSRI 0.50 ()0.10 to 1.04) 1.64 ns 0.44 ()0.16 to 1.04) 1.44 ns 0.23 (0.00 to 0.46) 2.00*
*Signiﬁcant at p < 0.05, **Signiﬁcant at p < 0.01.
Table 5 Correlations between BDI, BAI, SDQ-em and logarithmically trans-
formed HF, LF, SDNN analysed in the controls
HF LF SDNN
Partial correlations controlling for cardiovascular risk factors: BMI, p-glucose,
systolic and diastolic blood pressure
BDI )0.28* )0.14 ns )0.22 ns
BAI )0.22 ns 0.01 ns )0.13 ns
SDQ-em )0.26 ns )0.12 ns )0.18 ns
Partial correlations controlling for cardiovascular risk factors: BMI, p-glucose,
systolic and diastolic blood pressure and physical activity
BDI )0.26 ns )0.11 ns )0.20 ns
BAI )0.25 ns 0.00 ns )0.14 ns
SDQ-em )0.20 ns )0.06 ns )0.12 ns
ns = non-signiﬁcant.
*Signiﬁcant at p < 0.05.
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and DBP or physical activity, but partly by the effect of SSRI
medication. The present data failed to support that physio-
logical hyperarausal is speciﬁc for AD or that the decreased
HRV in depressed patients is explained by co-morbid anxi-
ety.
P-glucose was higher in the clinical sample, and could
have contributed to the difference of HRV between the
groups, even though p-glucose showed no contribution
to HRV in any of the samples. Physical activity and DBP
contributed to HRV in the non-clinical sample but not in
the clinical sample and there were no signiﬁcant differ-
ences of physical activity or DBP between the two
samples.
Medication with SSRI explained 15.5% of the total
variance of HF, 3.0% of LF and 6.5% of SDNN. This is in
line with earlier ﬁndings in adult samples where SRRI con-
tributed to a decrease of the RSA and SDNN in patients
with AD and MDD (14,15).
Our limited clinical sample size may explain the lack of
HRV difference between the diagnostic subgroups. The con-
trol sample of this study did not represent a true population
sample, which limits the inferential power. However, the
representativity of the control sample was supported by
comparison with a large population based study (females
n = 542), which showed that low RSA was related to
depressive symptoms but not to anxiety in adolescent
females (16). This compares well with data from our control
sample in which HF was related to depressive but not anx-
ious symptoms. Our analysis added the information that this
relationship not remained signiﬁcant after adjustment for
physical activity. Physical activity is known to be related to
increase of HRV in healthy adolescents (19). Physical activ-
ity was not correlated to BDI and BAI-score in the controls
in this study but patients with AD were more physically
active compared with patients with MDD or comorbidity of
AD⁄MDD (data not shown).
The HRV-registration method in 4 min episodes is similar
to the method used in a population based study (16). Four
minutes registration of HRV has been shown to have intra-
individual stability over 6 months in this age group (19).
In conclusion, adolescent females with AD, MDD and
comorbidity of AD⁄MDD show a decrease HRV compared
with healthy controls, which is partly explained by the effect
of SSRI. The ﬁndings do not support that the diagnoses of
AD and MDD can be differentiated by physiological hy-
perarousal in late adolescent girls. This is in line with earlier
population based studies of younger adolescents.
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